Skip to main content

Table 1 Baseline characteristics of patients with TED and HC donors

From: An L-type calcium channel blocker nimodipine exerts anti-fibrotic effects by attenuating TGF-β1 induced calcium response in an in vitro model of thyroid eye disease

Characteristics

Patients with TED

HC donors

Patients, n

6

6

Sex, male/female

3/3

3/3

Age, mean ± SD, years

50.83 ± 5.55

43.33 ± 13.61

History of smoking, n

3

1

Duration of illness, median (IQR), months

43.5 (39.75–51.25)

N/A

History of thyroid disease, n

 Graves’ disease

6

N/A

 Autoimmune thyroiditis

0

N/A

 Others

0

N/A

Previous thyroid treatments, n

 Drugs

6

N/A

 Radioiodine

1

N/A

 Thyroidectomy

1

N/A

Clinical Activity Score (CAS)a, n

 Inactive

6

N/A

 Active

0

N/A

Disease severityb, n

 Mild

0

N/A

 Moderate to severe

6

N/A

 Sight-threatening

0

N/A

  1. TED = thyroid eye disease; HC = healthy control; SD = standard deviation; n = number; N/A = not applicable
  2. aCAS was graded according to the 7-item Clinical Activity Score (CAS), CAS ≥ 3 indicates active and CAS < 3 indicates inactive
  3. bDisease severity was determined according to the European Group on Graves’ orbitopathy (EUGOGO) classification, which defines the severity as mild, moderate-to-severe, or sight-threatening